GEN Exclusives

More »

GEN News Highlights

More »
Oct 16, 2012

Kite, NCI Partner on Engineered Autologous T-Cell Therapies

  • T-cell therapeutics specialist Kite Pharma and the National Cancer Institute established a Cooperative Research and Development Agreement (CRADA) to develop and commercialize engineered peripheral blood autologous T-cell therapeutics (eACT) for treating multiple cancer indications. The deal gives Kite exclusive access to NCI’s current and future clinical pipeline of autologous peripheral blood T cells engineered using the latter’s tumor-specific T-cell receptors (TCRs), and chimeric antigen receptors (CARs), which are designed to target multiple blood and solid tumor types. The technology has been developed by team at NCI’s Surgery Branch, led by Steven A. Rosenberg. M.D.

    More specifically, the CRADA will focus on evaluating the clinical safety and efficacy of NCI’s eACT/TCR/CAR products in relevant cancer indications, generating an optimized large-scale cGMP manufacturing process for the products to allow multicenter trials and commercialization, and progressing new eACT/TCR/CAR products to clinical and developing technologies to further improve product potency.

    NCI-conducted clinical trials evaluating peripheral blood T cells engineered with TCRs or CARs have already demonstrated significant, durable clinical responses in cancer patients with advanced metastatic cancers, including refractory melanoma, sarcoma, lymphoma, and leukemia. “We regards eACT/TCR/CAR as a potential game-changing therapeutic approach to treat cancer patients,” comments Kite president and CEO Aya Jakobovits, M.D. “Kite will focus its efforts and resources to advance the NCI clinical product pipeline into multicenter studies aimed as successful registration and commercialization.”

    Kite was founded to work in partnership with Dr. Rosenberg’s team at NCI’s Surgery Branch to develop and commercialize the adoptive T-cell therapeutics platform. The firm raised $15 million in an initial round of private financing back in March 2011.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »